JCI Editorial Board potential conflicts of interest

First tier

AbbVie Pharmaceuticals (T.M. Dawson)

Aeras (M.L. Reitman)

Agenus (M.V. Maus)

Alliance for Lupus Research (M.J. Kaplan)

American Gene Technologies International (T.M. Dawson)

Amgen (D.A. Kass)

Ardelyx (M. Donowitz)

Biogen (P.A. Calabresi)

BluebirdBio (J.D. Powell)

Boehringer Ingelheim (D.A. Kass)

CHD Bioscience (W. Nelson)

Commonwealth Foundation (M.Y. Armanios)

Corvus (J.D. Powell)

CRISPR Therapeutics (M.V. Maus)

Deerfield Management Company LP (M. Laiho)

Digital Harmonic (W. Nelson)

Emulate (M. Donowitz)

Gemstone Biotherapeutics (S. Gerecht)

Genentech (S. Desiderio)

Gilead (T.C. Quinn)

Inhibikase (T.M. Dawson)

Intra-Cellular Therapies (D.A. Kass)

Ionis Pharmaceuticals (C. Sumner)

Janssen (A.M. DeMarzo)

Johnson & Johnson (A.P. Feinberg)

Loxo Oncology (B.H. Park)

MedImmune (P.A. Calabresi)

Merck (M. Donowitz)

miDiagnostics (S.C. Ray)

MycoMed Technologies (K.A. Marr)

Myriad Genetics (A.M. DeMarzo)

Navitor Pharmaceuticals (J.D. Powell)

Neuraly (T.M. Dawson)

NexImmune (J. Schneck)

Novartis (P.A. Calabresi)

Pfizer (D.A. Kass, W. Nelson)

ProQuest Investments (W. Nelson)

Sanofi (J.D. Powell)

SPARC (T.M. Dawson)

TCR2 Therapeutics (M.V. Maus)

Teva Pharmaceutical Industries Ltd. (P.A. Calabresi, W. Nelson)

Thermo Fisher (A.P. Feinberg)

Titan Pharmaceuticals (W.R. Bishai)

UD-GenoMed Medical Genomic Technologies Ltd. (L. Nagy)

Unum Therapeutics (M.V. Maus)

WindMIL Therapeutics (M.V. Maus)